A Digital Publication for the Practicing Medical Specialist, Industry Executive & Investor

No Carolina / New York

ARUP Laboratories Now Offers COVID-19 Saliva Testing – Available with Preapproval to ARUP Clients Nationwide

September 11, 2020

ARUP Laboratories reports their molecular diagnostic test is available with preapproval to ARUP clients nationwide. COVID-19 testing on saliva specimens offers significant benefits to both individuals and healthcare providers. Spitting into a funnel attached to the top of a collection tube is less invasive than a deep nasal swab performed by a healthcare provider. Providers benefit because they face less risk of exposure by infected individuals who cough or sneeze after enduring a nasopharyngeal swab.

ARUP Laboratories will perform the test only on saliva specimens collected using an ARUP collection kit with a healthcare provider present. ARUP validated the test using its kit on high-throughput instruments, and cannot perform it on other saliva specimens without jeopardizing quick turnaround times, said Adam Barker, Ph.D., director of ARUP’s new COVID-19 Rapid Response Lab.

“Offering accurate, high-quality COVID-19 testing and delivering results quickly to as many patients as possible is part of our commitment to excellent patient care,” Barker said.

ARUP moved quickly to offer COVID-19 saliva testing after researchers at ARUP and University of Utah Health found self-collected saliva and nasopharyngeal swabs collected by healthcare providers are equally effective for detecting SARS-CoV-2, the virus that causes COVID-19. Their study, published in the Journal of Clinical Microbiology, is one of the largest specimen-type comparisons to date.

U of U Health began offering ARUP’s COVID-19 saliva test on Sept. 1, and is using this specimen source to test for COVID-19 infection in most clinical settings. ARUP is a nonprofit enterprise of the U of U and its Department of Pathology. In addition to performing all testing for U of U Health, ARUP has thousands of hospital and health-system clients nationwide.

“We’re pleased to be one of the first labs to offer a COVID-19 saliva test that makes high-quality testing easier for patients and for providers,” said ARUP CEO Sherrie L. Perkins, MD, PhD. “ARUP remains committed to research, development and performance of tests that improve diagnosis of COVID-19 and all other diseases.”

In addition to COVID-19 molecular diagnostic testing, ARUP offers two IgG antibody tests to detect previous exposure to SARS-CoV-2. It also offers numerous tests that help guide treatment of the virus.

Medical Device News Magazinehttps://infomeddnews.com
Medical Device News Magazine provides breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

Under a license agreement, Biopredic will leverage Preci’s expertise and production capacity in sourcing primary hepatocytes, and combine with its own IP and know-how in cell pooling. The partnership will provide DMPK researchers access to large batches of high-performing suspended pooled hepatocytes with extended longevity from multiple donors.
The future of biotechnology holds immense promise, with continued advancements driving innovation and progress across various sectors. From gene editing and synthetic biology to biopharmaceuticals and beyond, the possibilities are endless. By staying informed, collaborating with industry leaders, and leveraging cutting-edge technologies, we can harness the power of biotechnology to address some of the most pressing challenges facing humanity.
"In a medical first, we have now dosed our first patient in a clinical trial using their own lymph nodes as living bioreactors to regenerate an ectopic organ," said Dr. Michael Hufford, Co-Founder and CEO of LyGenesis. "This therapy will potentially be a remarkable regenerative medicine milestone by helping patients with ESLD grow new functional ectopic livers in their own body. If our study is successful and we obtain FDA approval, our allogenic cell therapy could enable one donated liver to treat many dozens of ESLD patients, which could help to tilt the current organ supply-demand imbalance in favor of patients."
The relationship between pharmaceutical companies and CDMOs is fundamentally collaborative, fostering an environment of innovation. By partnering with a CDMO, pharmaceutical firms can access a wide array of technologies and expertise that might otherwise be beyond their reach.
Serum Detect is developing diagnostic tests, using standard liquid biopsy samples, that complement and enhance existing screening techniques for early detection of cancer.

By using this website you agree to accept Medical Device News Magazine Privacy Policy